Pear therapeutics investor presentation
WebJun 22, 2024 · SoftBank Group Corp's 9984.T $30 billion Vision Fund 2 led an $80 million Series D funding round in the startup in December. Pear is the latest SoftBank portfolio company to agree to a SPAC merger ... WebNov 14, 2024 · BOSTON – November 14, 2024 – Pear Therapeutics, Inc.(Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported results for …
Pear therapeutics investor presentation
Did you know?
WebApr 7, 2024 · The transaction includes a $50 million private investment in public equity (PIPE) from leading healthcare investors and thought leaders that are led by Farallon Capital Management, RS... WebJun 7, 2024 · Pear Therapeutics has set out its approach to clinical data and market access as it seeks a more than fivefold increase in revenue for its prescription digital therapeutics in 2024. ... the stock-price decline on the investor day event occurred when the markets opened and before the start of the company' presentation. At the event, Pear ...
WebEX-99.1 PEAR THERAPEUTICS INC INVESTOR PRESENTATION 11 JANUARY 2024 ex-991ptipresentation11j 1 Software-based Medicines for the Treatment of Serious Disease Prescription Digital Therapeutics Investor Presentation January 2024 Copyright 2024, Pear Therapeutics, Inc. All rights reserved. WebBoston 200 State Street Boston, MA 02109 San Francisco 201 Mission Street San Francisco, CA 94105
WebApr 6, 2024 · A high-level overview of Pear Therapeutics, Inc. (PEAR) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. WebNov 14, 2024 · Net Revenue and Key Operating Metrics* Q3 2024 Actual Full Year 2024 Guidance Net Revenue $4.1 million $14-16 million Total Prescriptions 11,400+ 35,000-45,000 Fulfillment Rate
WebFind the latest Pear Therapeutics, Inc. (PEAR) stock quote, history, news and other vital information to help you with your stock trading and investing.
WebNov 14, 2024 · BOSTON – November 14, 2024 – Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription … thiorax phytoWebJun 22, 2024 · Investors that include the Pritzker Vlock Family Office and Neuberger Berman Group funds are backing a roughly $125 million private investment in public equity, or PIPE, as part of the proposed deal. thioravirocWebApr 12, 2024 · Remembering back from their S-1 and investor day presentations, this spend included a large HCP sales effort in advance of securing broad payer coverage, and in the … thioredoxin 1 antibodyWebMar 28, 2024 · BOSTON–(BUSINESS WIRE)–Mar. 28, 2024– Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, … thiorcula saws for sale in nWebJun 22, 2024 · By the end of 2024, Pear expects to bring in just $4 million in revenue, according to an investor presentation. By 2024, the company estimates it will see $125 million in revenue, a... thioredoxin and glutathione systemsWebJan 18, 2024 · Pear Therapeutics Announces Process Exploring Strategic Alternatives March 17, 2024. Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference February 27, 2024. Pear Therapeutics to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference February 2, 2024. thiorax produit phytoWebMay 16, 2024 · Pear's first 12-month and 24-month real-world health economic data presented at ISPOR. BOSTON -- (BUSINESS WIRE)--May 16, 2024-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported financial results for its first … thioredoxin 2